Phase 2 randomized placebo-controlled study of crofelemer in adults with short bowel syndrome–intestinal failure without colon in continuity

Phase 2, randomised, double-blind trial of crofelemer in short bowel syndrome (SBS) and intestinal failure (IF) (3 arms), sponsored by Napo Therapeutics. Primary endpoints: Frequency of treatment-emergent adverse events, Frequency of investigational product interruption or discontinuation and 2 more. Planned start Mar 2025; status: authorised.